Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Ingresos
142
139
89
49
22
14
Crecimiento de los Ingresos (YoY)
11%
56%
82%
123%
56.99%
600%
Costo de los ingresos
35
40
35
27
18
12
Utilidad bruta
106
98
53
21
4
1
Venta, General y Administración
113
101
74
58
33
15
Investigación y Desarrollo
38
34
28
25
24
21
Gastos de Operación
152
135
103
84
57
37
Otras Ingresos (Gastos) No Operativos
--
--
--
0
7
63
Ingreso antes de impuestos
-35
-27
-48
-66
-48
27
Gasto por Impuesto a la Renta
0
0
0
0
0
0
Ingreso Neto
-35
-27
-48
-66
-48
3
Crecimiento de la Utilidad Neta
17%
-44%
-27%
38%
-1,700%
-88%
Acciones en Circulación (Diluidas)
40.96
38.86
34.45
28.27
27.37
26.29
Cambio de Acciones (YoY)
3%
13%
22%
3%
4%
0%
EPS (Diluido)
-0.87
-0.7
-1.41
-2.36
-1.78
0.13
Crecimiento de EPS
14%
-50%
-40%
33%
-1,469%
-87%
Flujo de efectivo libre
-22
-22
-46
-61
-46
-37
Flujo de efectivo libre por acción
--
--
--
--
--
--
Margen bruto
74.64%
70.5%
59.55%
42.85%
18.18%
7.14%
Margen de operación
-31.69%
-25.89%
-56.17%
-128.57%
-236.36%
-250%
Margen de beneficio
-24.64%
-19.42%
-53.93%
-134.69%
-218.18%
21.42%
Margen de flujo de caja libre
-15.49%
-15.82%
-51.68%
-124.48%
-209.09%
-264.28%
EBITDA
-43
-36
-50
-63
-52
-35
Margen de EBITDA
-30.28%
-25.89%
-56.17%
-128.57%
-236.36%
-250%
D&A para EBITDA
2
0
0
0
0
0
EBIT
-45
-36
-50
-63
-52
-35
Margen de EBIT
-31.69%
-25.89%
-56.17%
-128.57%
-236.36%
-250%
Tasa de Impuesto Efectiva
0%
0%
0%
0%
0%
0%
Estadísticas clave
Cierre Anterior
$7.8
Precio de apertura
$7.81
Rango del día
$7.81 - $8.31
Rango de 52 semanas
$6.32 - $34.71
Volumen
496.0K
Volumen promedio
861.0K
EPS (TTM)
-0.88
Rendimiento de dividendos
--
Cap. de mercado
$330.6M
¿Qué es RXST?
RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. The company is headquartered in Aliso Viejo, California and currently employs 498 full-time employees. The company went IPO on 2021-07-30. The firm's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.